What a Cycle Is and Why There Is a Rest Period
Chemotherapy is systemic treatment with drugs that kill rapidly dividing cells or stop them dividing. Because it also affects healthy fast-dividing cells in the bone marrow, mouth and gut lining, it is given in blocks rather than continuously. One cycle (sometimes called a round or a course in everyday speech) is the day or days on which the drug is given plus the rest period that follows.
A cycle may be 7, 14, 21 or 28 days. "Six cycles every 21 days" means the drug is given on day 1, the patient rests for 20 days and cycle two starts on day 22; the whole course takes about 18 weeks. Some regimens give the drug on several consecutive days, or on days 1 and 8 of each cycle. Cycles and sessions are not the same thing: a weekly drug given 12 times may correspond to four 28-day cycles.
The rest period is not arbitrary. White blood cells usually reach their lowest point between days 7 and 14 and recover by around day 21; the interval was chosen in trials to keep the drug's effect while allowing that recovery. Routes of administration and side effects are covered on the chemotherapy page.
The Aim of Treatment Sets the Number
The first question that determines the number of cycles is what the treatment is for. The same drug in the same cancer can be given for different lengths depending on the setting.
- Adjuvant treatment (after surgery)
- The tumour has been removed; the aim is to destroy microscopic cells that may remain and reduce the risk of recurrence. There is nothing to measure on a scan, so the number of cycles is fixed in advance and follows the length tested in trials, usually 3 to 6 months.
- Neoadjuvant treatment (before surgery)
- The aim is to shrink the tumour, make the operation easier and see how the cancer responds to the drug while it is still measurable. The number of cycles is planned in advance, but imaging during treatment can change the plan if the tumour grows.
- Treatment of metastatic disease
- The aim is to control the cancer, relieve symptoms and extend life. There is no fixed total; scans every two to three cycles decide whether to continue, de-escalate to maintenance or switch.
- Curative chemotherapy
- In lymphomas, germ cell tumours and some other cancers, chemotherapy alone can be curative. Cycle number and dose intensity are tightly defined, and reducing them can directly affect the outcome.
Is Chemotherapy Always Needed in Early Hormone Positive Disease
The TAILORx study presented at the San Antonio Breast Cancer Symposium changed the chemotherapy decision; the video explains for whom it can be avoided.
Typical Cycle Counts by Cancer Type
The table gives cycle counts from regimens that appear in ESMO and NCCN guidelines. They are examples, not prescriptions: the oncologist chooses the regimen according to kidney and liver function, age, other illnesses and the molecular features of the tumour.
| Cancer and setting | Typical regimen | Cycles and duration |
|---|---|---|
| Breast cancer, adjuvant | Anthracycline followed by a taxane | 4 + 4 cycles, or 4 cycles then 12 weekly doses; about 4 to 6 months |
| Colon cancer stage III, adjuvant | CAPOX or FOLFOX | 3 months (4 cycles of CAPOX) in low-risk disease; 6 months (12 cycles of FOLFOX) in high-risk disease |
| Non-small cell lung cancer, adjuvant | Cisplatin-based doublet | 4 cycles every 21 days; about 3 months |
| Stomach cancer, perioperative | FLOT | 4 cycles before and 4 after surgery, every 14 days |
| Metastatic colorectal cancer, first line | FOLFOX or FOLFIRI with a targeted antibody | Usually 8 to 12 induction cycles, then maintenance; no fixed total |
| Metastatic non-small cell lung cancer | Platinum doublet with immunotherapy | 4 cycles of chemotherapy, then immunotherapy alone as maintenance |
Colon cancer shows how a cycle count is decided by evidence rather than habit. The IDEA collaboration pooled more than 12,000 patients from six trials and found that three months of CAPOX gave protection very close to six months in low-risk stage III disease, with far less lasting nerve damage. Adjuvant treatment for colorectal cancer is now three or six months according to tumour depth and lymph node involvement.
Send Your Reports for Assessment
Share your pathology, imaging and blood results on WhatsApp, or send them by email. Documents are reviewed before the consultation.
Interim Scans and Response-Guided Decisions
In metastatic disease and before surgery, the number of cycles depends on interim assessment. This is usually a CT or PET-CT scan after every two or three cycles (6 to 12 weeks), comparing tumour measurements with the baseline scan. The international RECIST 1.1 criteria define the outcome: a 30 percent or greater fall in the sum of tumour diameters is a partial response, a 20 percent or greater rise is progression, and anything in between is stable disease.
If the scan shows response or stable disease, treatment continues. After a set number of cycles the oncologist may switch to a lighter maintenance phase to limit cumulative side effects. In metastatic colorectal cancer the CAIRO3 trial showed that maintenance with capecitabine and bevacizumab after six cycles of CAPOX and bevacizumab delayed progression compared with a complete break. In metastatic lung cancer the chemotherapy component is limited to four cycles while immunotherapy continues alone.
If the scan shows progression, a second-line treatment is chosen. The tumour's molecular profile is reviewed again, and for some patients comprehensive genomic profiling identifies a targeted drug instead of further chemotherapy.
Important: The number of cycles is not decided on the principle that more is better. Chemotherapy beyond the tested duration does not lower the risk of recurrence further, but it does increase cumulative harm such as permanent nerve damage and effects on the heart and kidneys. Nothing on this page replaces a consultation with your own oncologist.
Can Disease Progress Despite Hormone Therapy
In a patient who had completed chemotherapy and started hormone therapy, metastatic deposits were found in the liver at the third-month review; the video explains how that is assessed.
Delays, Dose Reductions and Stopping Early
Before every cycle, a blood count and kidney and liver tests are checked. If the neutrophil count (the white cells that fight infection) or the platelet count is below the safe threshold, the cycle is usually postponed by a week. Fever, active infection, uncontrolled diarrhoea or mouth ulcers are also reasons to wait.
When a Dose Is Reduced
If the previous cycle caused a serious side effect, such as febrile neutropenia, grade 3 diarrhoea or marked neuropathy, the next dose may be reduced by 20 to 25 percent. A reduced dose does not mean the treatment will not work; guidelines aim to preserve overall dose intensity, but patient safety comes first. Growth-factor injections (G-CSF) can keep high-risk regimens on schedule.
Reasons to Stop Before the Planned Number
- Progression on an interim scan
- A repeated or life-threatening side effect
- A decline in general fitness (performance status) that makes further treatment unsafe
- The patient's own informed decision to stop
When an adjuvant course cannot be completed, the cycles already given still provide part of the protective effect. Fever after chemotherapy is an emergency; the rules for seeking help are in the patient guide.
How the Number Is Agreed with the Patient
Before treatment starts, Prof. Dr. H. Ibrahim Petekkaya gives each patient the regimen name, the number of cycles, the interval and the total duration in writing. The consultation covers three questions: Which trial or guideline is this number based on? Is there a shorter option, and what would it cost in protection? When is the first interim scan, and what could change after it?
During treatment, side effects are graded before every cycle and the plan is adjusted if needed. Scan results are shared with the patient, and the decision to continue, de-escalate or switch is explained with its reasoning. Difficult cases go to the hospital tumour board or, where the molecular profile matters, the molecular tumour board. Patients who want an independent view on a plan drawn up elsewhere can use the second opinion service; those coming from abroad will find the practical steps on the international patients page, and a treatment summary with regimen, doses and cycle dates is prepared so that cycles can continue with a home oncologist without gaps.
The short answer to "how many cycles will I have" is therefore two answers: a fixed, evidence-based number in adjuvant and neoadjuvant treatment, and a flexible plan reviewed by response and tolerance in metastatic disease. In both cases the number comes from data for patients like you, not from a rule of thumb, and it is set with you rather than for you. Patients who want the plan looked at again before starting can use the second opinion process.
Frequently Asked Questions
How long is one chemotherapy cycle?
A cycle is the treatment day or days plus the rest period that follows, and it is usually 7, 14, 21 or 28 days long. Weekly regimens give smaller doses often; three-weekly regimens give a larger dose once. The length is fixed by the trials that tested the regimen so that blood counts and the lining of the gut recover before the next dose. It should not be shortened or stretched without the oncologist's decision.
How many rounds of chemo is normal?
There is no single normal number. After surgery, most regimens run for 3 to 6 months, which is typically 4 to 12 cycles depending on the cycle length. Before surgery, courses of 2 to 6 months are usual. In metastatic disease there is no preset total: treatment continues while scans show benefit and side effects are acceptable, often moving to a gentler maintenance phase. The number is set per cancer type and per patient.
Can chemotherapy be stopped early?
Yes. Progression on an interim scan, a serious or repeated side effect, a decline in general fitness or the patient's own informed decision are the main reasons. Sometimes a shorter course is itself evidence-based: in low-risk stage III colon cancer, three months of CAPOX gives protection close to six months with much less nerve damage. Stopping early is always a joint decision with the oncologist, not a sign that treatment has failed.
Does delaying a cycle by a week reduce the effect?
A single one-week delay is common and does not meaningfully change the outcome. Delays are usually for low neutrophil or platelet counts or an infection, and treating through them would be more harmful than waiting. If delays become repeated or long, the oncologist reviews the regimen to protect overall dose intensity, sometimes with growth-factor injections. Patients should never postpone a cycle on their own.
Why do some cancers need more cycles than others?
Each regimen was tested at a specific number of cycles, and that is the number guidelines recommend. Adjuvant breast cancer regimens often total 4 to 8 cycles; adjuvant lung cancer chemotherapy is 4 cycles; perioperative stomach cancer treatment is 4 cycles before and 4 after surgery; stage III colon cancer is 3 or 6 months by risk group. Giving more cycles than the tested number does not add protection but adds cumulative toxicity.
Can I discuss or question the number of cycles planned?
Yes, and you should. Ask which trial or guideline the number is based on, whether a shorter option exists and what it would cost in protection, when the first interim scan is planned and what could change afterwards. Prof. Dr. H. Ibrahim Petekkaya gives patients the regimen name, cycle count, interval and total duration in writing before the first dose, and documents the shared decision.
Related Articles
What Does VUS Mean on an NGS Report, and How Do You Read the Rest of It?
Sayfayı Açın
Why Biomarkers Set the Treatment Order in Metastatic Colorectal Cancer
Sayfayı AçınRelated Pages
Chemotherapy
Sayfayı Açın
Colorectal Cancer
Sayfayı Açın
Breast Cancer
Sayfayı Açın
Treatment Pathway
Sayfayı Açın
Second Opinion
Sayfayı AçınSources and Guidelines
- ESMO Clinical Practice Guidelines, by cancer type. Link
- NCCN Guidelines for Treatment of Cancer by Site. Link
- Grothey A et al. Duration of adjuvant chemotherapy for stage III colon cancer (IDEA). N Engl J Med 2018;378:1177-1188. Link
- Loibl S et al. Early breast cancer: ESMO Clinical Practice Guideline. Ann Oncol 2024;35(2):159-182. Link
- Remon J et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2021;32(12):1637-1642. Link
- Lordick F et al. Gastric cancer: ESMO Clinical Practice Guideline. Ann Oncol 2022;33(10):1005-1020. Link
- Simkens LHJ et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3). Lancet 2015;385:1843-1852. Link
- Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. Link
- Klastersky J et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016;27(suppl 5):v111-v118. Link
- Cancer Research UK. Chemotherapy: how it works and what to expect. Link